drugset / Trial / NCT05331222

Proof-of-Concept Interventional Study With a Nasal Spray of JT-1 in Patients With Chronic Rhinitis or Chronic Sinusitis

NCT05331222 ↗

Terminated 3 enrolled Jantar GmbH
NaSingle-groupOpen-labelTreatment

Summary

Proof-of-concept study with a novel nasal spray in chronic rhinitis or chronic sinusitis. The study will involve 25 patients completing the study for a per protocol analysis.

Timeline

Start
2022-09-30
Primary completion
2023-03-03
Completion
2023-03-03

Outcome

Outcome not reported

Stopped: “regulatory issues”

Drugs

EvaluationDrugModalityDoseRoute
Subject JT-1 Unknown 7 % Intranasal